Not applicableNo Longer AvailableNCT04518644What this trial is testingNilotinib, for Patients With CML-CP or CML-APWho this might be right forChronic Myelogenous Leukemia (CML) Novartis Pharmaceuticals
Early research (Phase 1)WithdrawnNCT03414450What this trial is testingEvaluation of ETC-1907206 With Dasatinib in Advanced Haematologic MalignanciesWho this might be right forPh+ Acute Lymphoblastic Leukemia (Ph+ALL)Ph- Acute Lymphoblastic Leukemia (Ph-ALL)Chronic Myeloid Leukemia Accelerated Phase (CML-AP, Ph+)+1 more EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Testing effectiveness (Phase 2)Study completedNCT01844765What this trial is testingOpen Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.Who this might be right forPhiladelphia Positive (Ph+) Chronic Myelogenous Leukemia Novartis Pharmaceuticals 59
Not applicableEnded earlyNCT02455024What this trial is testingAn Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®Who this might be right forMyeloid Leukemia, Chronic-Phase, Accelerated-Phase, Blast-Phase, Ph+ALL Ariad Pharmaceuticals 3
Testing effectiveness (Phase 2)Study completedNCT00381550What this trial is testing3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAtypical Chronic Myeloid Leukemia, BCR-ABL1 NegativeBlastic Phase Chronic Myelogenous Leukemia+7 more National Cancer Institute (NCI) 35
Early research (Phase 1)Study completedNCT01077544What this trial is testingA Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)Who this might be right forChronic Myeloid LeukemiaAcute Lymphoblastic Leukemia Novartis Pharmaceuticals 15